基本信息
姓名: 卢红阳 性别: 男
学历: 研究生 学位: 博士(硕导)
职称: 主任医师 出生年份: 1977
博导类型: 博导专业: 博导学院:
硕导类型: 学术型/专业型 硕导专业: 肿瘤学 硕导学院: 第二临床医学院
Email: luhy@zjcc.org.cn 联系电话: +86-
研究方向:
工作单位: 附属肿瘤医院
发表论文
1、Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma,卢红阳,毛伟敏, BMC Cancer,SCI,2018-03,浙江省肿瘤医院,三区,2.933,251

---

2、1p/19q codeletion and RET rearrangements in small-cell lung cancer,卢红阳,毛伟敏,OncoTargets and Therapy,SCI,2016-06,浙江省肿瘤医院,四区,2.612,3571-3577

---

3、PIK3CA Mutations in Resected Small Cell Lung Cancer,韩娜,卢红阳, BMC Cancer,SCI,2016-05,浙江省肿瘤医院,四区,1.179,397-402

---

4、The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma,金向宇,卢红阳,Clinical Laboratory,SCI,2017-04,浙江省肿瘤医院,四区,0.848,801-808

---

5、O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer,卢红阳,毛伟敏,Experimental and Therapeutic Medicine,SCI,2017-07,浙江省肿瘤医院,四区,1.448,398-402

---

6、Preoperative serum carcinoembryonic antigen levels are associated with histologic subtype, EGFR mutations, and ALK fusion in patients with completely resected lung adenocarcinoma,王增,卢红阳,OncoTargets and Therapy,SCI,2017-07,浙江省肿瘤医院,四区,2.656,3345-3351

---

7、Advances in antiangiogenic treatment of small-cell lung cancer,卢红阳,卢红阳,OncoTargets and Therapy,SCI,2017-01,浙江省肿瘤医院,四区,2.656,353-359

---

8、Usefulness of carcinoembryonic antigen in the diagnosis of small cell lung cancer combined with adenocarcinoma,雷蕾,卢红阳,Advances In Clinical And Experimental Medicine,SCI,2017-10,浙江省肿瘤医院,四区,1.262,1091-1094

---

9、Clinical and pathological findings of surgically resected patients for lung adenocarcinomas harboring uncommon EGFR mutations,杨世峰,卢红阳,International Journal of Clinical and Experimental Pathology,SCI,2017-07,浙江省肿瘤医院,四区,1.396,7627-7631

---

10、Adenosquamous Carcinoma of the Lung,李成辉,卢红阳,OncoTargets and Therapy,SCI,2018-08,浙江省肿瘤医院,四区,3.046,4829-4835

---

11、Telomerase reverse transcriptase promoter region mutations and the clinical characteristics of pulmonary neuroendocrine tumors,李成辉,卢红阳,Translational Cancer Research,SCI,2018-02,浙江省肿瘤医院,四区,1.07,10-16

---

12、Combined small-cell lung carcinoma,覃晶,卢红阳,OncoTargets and Therapy,SCI,2018-06,浙江省肿瘤医院,四区,3.046,3505-3511

---

13、EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients,卢红阳,卢红阳,OncoTargets and Therapy,SCI,2018-04,浙江省肿瘤医院,四区,3.046,2217-2226

---

14、The role and mechanism of Borneol to open the Blood-Brain Barrier,吴涛,卢红阳,Integrative Cancer Therapies,SCI,2018-09,浙江省肿瘤医院,四区,2.634,806-812

---

15、Effect of metformin in the prognosis of patients with small- cell lung cancer combined with diabetes mellitus,卢红阳,毛伟敏,Advances In Clinical And Experimental Medicine,SCI,2018-09,浙江省肿瘤医院,四区,1.227,1195-1199

---

16、Advances in antibody therapeutics targeting small-cell lung cancer,卢红阳,卢红阳,Advances In Clinical And Experimental Medicine,SCI,2018-09,浙江省肿瘤医院,四区,1.227,1317-1323

---

17、MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma,雷蕾,卢红阳,World Journal of Surgical Oncology,SCI,2018-06,浙江省肿瘤医院,四区,1.966,110

---

18、Invasive mucinous adenocarcinoma of the lung,徐璐,卢红阳,Translational Cancer Research,SCI,2019-09,永康第一人民医院,四区,1.07,2924-2932

---

19、EGFR exon 20 insertion mutations in non-small cell lung cancer,王芬芳,卢红阳,Translational Cancer Research,SCI,2020-04,象山第一人民医院,四区,1.07,2982-2991

---

20、KRAS Exon 3 and PTEN Exon 7 Mutation in Small-cell Lung Cancer,雷蕾,卢红阳,Current Medical Science,SCI,2019-06,浙江省肿瘤医院,四区,0.957,379-384

---

21、Is prophylactic cranial irradiation necessary in individuals suffering from surgically resected pT1-2N0M0 small cell lung cancer?,卢红阳,卢红阳,Irish Journal of Medical Science,SCI,2019-08,浙江省肿瘤医院,四区,1.031,761-764

---

22、Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small-Cell Lung Cancer,卢红阳,卢红阳,Integrative Cancer Therapies,SCI,2018-12,浙江省肿瘤医院,四区,2.634,1109–1114

---

23、 Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response,覃晶,卢红阳,Translational Cancer Research,SCI,2019-09,浙江省肿瘤医院,四区,1.07,2187-2191

---

24、Molecular genetic profiling of small cell lung carcinoma in a Chinese cohort,王增,卢红阳,Translational Cancer Research,SCI,2019-02,浙江省肿瘤医院,四区,1.07,255-261

---

25、Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib,王芬芳,卢红阳,Lung cancer,SCI,2020-02,象山第一人民医院,三区,4.599,118–120

---

26、Primary pulmonary lymphoepithelioma-like carcinoma,樊滢,卢红阳,Medical Oncology,SCI,2020-03,温州医科大学,四区,3.252,20

---

27、The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient With Afatinib-Resistant Lung Cancer,龚磊,卢红阳,Journal of Thoracic Oncology,SCI,2019-06,浙江省肿瘤医院,一区,12.46,e120–e123

---

科研项目
1、冰片对H2受体介导组胺开放血脑肿瘤屏障的作用及机制,卢红阳,浙江省肿瘤医院,国家自然科学基金,国家级,,2015-12,23,23

---

2、小细胞肺癌化疗耐药后向腺癌表型转化的研究,卢红阳,浙江省肿瘤医院,浙江省公益技术应用研究计划,省部级,2016-01,2018-12,15,15

---

3、茶多酚活性成分EGCG对Snail介导抑制“EMT-干性”逆转小细胞肺癌顺铂耐药的作用及机制,卢红阳,浙江省肿瘤医院,浙江省自然科学基金,省部级,2015-01,2017-12,9,9

---

4、冰片通过调控caveolin-1逆转小细胞肺癌顺铂耐药的作用及机制,卢红阳,浙江省肿瘤医院,浙江省自然科学基金,省部级,2020-01,2022-12,9,9

---

科研成果
1、局限期小细胞肺癌放化综合治疗模式优化策略,马胜林,3,杭州市第一人民医院,浙江省科学技术奖,三等奖,2016-12

---

2、肺癌综合诊疗关键技术创新与临床推广应用,毛伟敏,13,浙江省肿瘤医院,教育部科学技术进步奖,二等奖,2017-02

---

3、局限期小细胞肺癌放化综合治疗模式的研究,马胜林,4,杭州市第一人民医院,杭州市科技进步奖,一等奖,2014-09

---

个人信息
卢红阳，男，1977年9月出生，医学博士，主任医师，2002年6月毕业于浙江大学医学院临床医学七年制，获硕士学位，同年至浙江省肿瘤医院肿瘤内科工作至今，2008年毕业于浙江中医药大学中西医结合临床（肿瘤学方向）专业，获博士学位。浙江省肿瘤医院胸部肿瘤内科病区副主任，浙江省“151”人才第三层次，浙江省医坛新秀，国家自然科学基金同行评议专家，中国抗癌协会肺癌专业委员会第二届青年委员会副主任委员，浙江省抗癌协会肺癌专业委员会委员兼秘书等。从事肿瘤内科临床工作近20年，擅长胸部肿瘤的内科治疗。以第一作者或通讯作者在国内外核心期刊发表学术论文70多篇（其中 SCI收录论文30余篇），主持国家自然科学基金1项、省部级课题4项、厅局级及其他课题10余项，以第一完成人获浙江省医药卫生科技奖二等奖1项及国家发明专利1项，参与获浙江省科学技术奖二等奖及三等奖各1项，副主编著作1部。